202 related articles for article (PubMed ID: 19305985)
21. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
Kontou A; Sarafidis K; Begou O; Gika HG; Tsiligiannis A; Ogungbenro K; Dokoumetzidis A; Agakidou E; Roilides E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932366
[TBL] [Abstract][Full Text] [Related]
22. Amikacin population pharmacokinetics among paediatric burn patients.
Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
[TBL] [Abstract][Full Text] [Related]
23. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
Lugo G; Castañeda-Hernández G
Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation.
Bleyzac N; Varnier V; Labaune JM; Corvaisier S; Maire P; Jelliffe RW; Putet G; Aulagner G
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):499-504. PubMed ID: 11699615
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacokinetics of netilmicin in neonates].
Piekarczyk A; Kaminska E; Taljanski W; Sosonowska K; Poszwinska B; Rutkowska M
Med Wieku Rozwoj; 2003; 7(4 Pt 2):547-55. PubMed ID: 15213369
[TBL] [Abstract][Full Text] [Related]
26. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates.
Allegaert K; Scheers I; Adams E; Brajanoski G; Cossey V; Anderson BJ
Antimicrob Agents Chemother; 2008 Jun; 52(6):1934-9. PubMed ID: 18378715
[TBL] [Abstract][Full Text] [Related]
28. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
[TBL] [Abstract][Full Text] [Related]
29. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of amikacin in neonates.
Padovani EM; Pistolesi C; Fanos V; Messori A; Martini N
Dev Pharmacol Ther; 1993; 20(3-4):167-73. PubMed ID: 7828449
[TBL] [Abstract][Full Text] [Related]
31. Limited predictability of amikacin clearance in extreme premature neonates at birth.
Allegaert K; Anderson BJ; Cossey V; Holford NH
Br J Clin Pharmacol; 2006 Jan; 61(1):39-48. PubMed ID: 16390350
[TBL] [Abstract][Full Text] [Related]
32. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize
Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443
[TBL] [Abstract][Full Text] [Related]
33. Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low-birth-weight infants.
Allegaert K; Debeer A; Cossey V; Rayyan M; Devlieger H
Pediatr Crit Care Med; 2006 Mar; 7(2):143-6. PubMed ID: 16446602
[TBL] [Abstract][Full Text] [Related]
34. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.
Najmeddin F; Ahmadi A; Mahmoudi L; Sadeghi K; Khalili H; Ahmadvand A; Najafi A; Mojtahedzadeh M
Acta Med Iran; 2014; 52(9):703-9. PubMed ID: 25325208
[TBL] [Abstract][Full Text] [Related]
35. [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Elkhaïli H; Pompei D; Peter JD; Linger L; Salmon J; Levêque D; Niedergang S; Salmon Y; Thierry RC; Monteil H; Jehl F
Pathol Biol (Paris); 1997 May; 45(5):347-56. PubMed ID: 9296083
[TBL] [Abstract][Full Text] [Related]
36. Amikacin dosing in neonates: evaluation of a dosing chart based on population pharmacokinetic data.
Petersen PO; Wells TG; Kearns GL
Dev Pharmacol Ther; 1991; 16(4):203-11. PubMed ID: 1782838
[TBL] [Abstract][Full Text] [Related]
37. Renal drug clearance in preterm neonates: relation to prenatal growth.
Allegaert K; Anderson BJ; van den Anker JN; Vanhaesebrouck S; de Zegher F
Ther Drug Monit; 2007 Jun; 29(3):284-91. PubMed ID: 17529884
[TBL] [Abstract][Full Text] [Related]
38. Impact of ibuprofen administration on renal drug clearance in the first weeks of life.
Allegaert K; Rayyan M; Anderson BJ
Methods Find Exp Clin Pharmacol; 2006 Oct; 28(8):519-22. PubMed ID: 17136231
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
[TBL] [Abstract][Full Text] [Related]
40. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
